Muscle in Acromegaly and Cushing's Syndrome (MAC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03673761

Recruitment Status : Unknown

Verified February 2019 by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau.
Recruitment status was: Recruiting

First Posted : September 17, 2018

Last Update Posted : February 25, 2019

Sponsor:

Information provided by (Responsible Party):

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Study Description

Brief Summary:

Cushing's syndrome (CS) and acromegaly determine myopathy and muscle weakness which persist long-term after control of hormone excess. Fatty infiltration in skeletal muscle (myosteatosis) is associated with muscle atrophy, frailty, and increased morbidity and mortality in several human models. The study is aimed at evaluating muscle structure in patients with controlled CS and acromegaly, and correlate it with functional tests of muscle strength. In addition, circulating molecules potentially mediating persistent myopathy in these patients will also be assessed.

Condition or disease	Intervention/treatment
Cushing Syndrome Acromegaly	Other: MRI, dual-energy, x-ray absorptiometry, muscle ultrasounds, blood testing

Detailed Description:

Prior chronic exposure to glucocorticoids or growth hormone (GH) determines fat infiltration and persistent impairment of muscle structure in "cured" patients with CS or acromegaly, respectively. All this leads to irreversible changes in muscle strength and performance, markedly affecting morbidity and quality of life of these patients. In particular, muscle weakness would contribute significantly to the development of severe arthropathy associated with excess GH, as well as deterioration of bone status and increased risk of fracture, as described in patients with either CS or acromegaly in remission. Our aim is to evaluate whether muscular MRI is a useful tool for the assessment of myopathy and myosteatosis in these patients. If this is the case, we would have identified a non-invasive test that would allow the follow-up of patients at risk of developing functional motor problems, anticipating the onset of muscle weakness or fatigue and consequent deterioration of their quality of life. On the other hand, we will examine the role of microRNAs, which can suppress the process of myogenic differentiation, as potential modulators of myopathy in these conditions. Indeed, microRNAs could be used in clinical practice as markers to identify patients at risk of myopathy, and develop strategies for their prevention. Clarifying the impact of muscle fat infiltration on muscle strength would allow us to better understand the interaction between muscle and adipose tissue, encouraging research on potential mediators of this relationship, such as myostatin (MSTN) (able to direct the mesenchymal cell muscle towards the formation of adipocytes at the expense of myocytes) and adiponectin (ApN) (which keeps the levels of fat in the muscle low while favoring the formation and regeneration of muscle tissue).

Study Design

Layout table for study information

Study Type :	Observational
Estimated Enrollment :	120 participants
Observational Model:	Case-Control
Time Perspective:	Cross-Sectional
Official Title:	Role of Myosteatosis in the Occurrence and Persistence of Residual Muscle Weakness in Patients With Acromegaly and Cushing's Syndrome. Study of the Mechanisms Involved
Actual Study Start Date :	February 1, 2018
Estimated Primary Completion Date :	October 31, 2019
Estimated Study Completion Date :	January 31, 2020

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Cushing disease

MedlinePlus related topics: Cushing's Syndrome

Drug Information available for: X-Rays

Genetic and Rare Diseases Information Center resources: Cushing's Syndrome Acromegaly Hyperadrenalism

U.S. FDA Resources

Groups and Cohorts

Group/Cohort	Intervention/treatment
Cushing's syndrome a) Patients with Sd Cushing (SC): 40 women (25-60 years) with SC, with controlled hypercortisolism after treatment and without clinical / biochemical signs of relapse for more than 5 years. This group will under go the following procedures: muscle MRI dual-energy x-ray absorptiometry muscle ultrasounds blood testing	Other: MRI, dual-energy, x-ray absorptiometry, muscle ultrasounds, blood testing 3.Dixon, T2 mapping MRI microRNAs
acromegaly b) Patients with acromegaly: 40 patients of both sexes (25-60 years) with GH / Insulin-like-Growth Factor (IGF-I) controlled after treatment and without clinical / biochemical signs of relapse for more than 5 years. This group will under go the following procedures: muscle MRI dual-energy x-ray absorptiometry muscle ultrasounds blood testing	Other: MRI, dual-energy, x-ray absorptiometry, muscle ultrasounds, blood testing 3.Dixon, T2 mapping MRI microRNAs
Healthy controls Controls: n = 40; normal healthy control paired by age, sex and BMI will be included. This group will under go the following procedures: muscle MRI dual-energy x-ray absorptiometry muscle ultrasounds blood testing	Other: MRI, dual-energy, x-ray absorptiometry, muscle ultrasounds, blood testing 3.Dixon, T2 mapping MRI microRNAs

Outcome Measures

Primary Outcome Measures :

MRI assessment of fatty infiltration in tigh muscles. [ Time Frame: Within one year since recruitment ]
Quantitative muscle 3Tesla-MRI (mappting T2 and 3.Dixon) will be used. Assessment of fatty infiltration as well as measurement of necrosis and inflammation areas in tigh muscles will be performed.

Secondary Outcome Measures :

microRNAs [ Time Frame: Within one year since recruitment ]
A bioinformatic study will be carried out to select a set of miRNAs differentially expressed in acromegaly and Cushing's syndrome as compared with controls. The miRNAs will be selected according to the pathophysiological pathways (GO, KEGG) in which they are involved and taking into account the pathophysiology of Cushing's syndrome and acromegaly. Differentially expressed miRNAs will be then related to primary outcome measures.

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	18 Years to 65 Years (Adult, Older Adult)
Sexes Eligible for Study:	Female
Accepts Healthy Volunteers:	Yes
Sampling Method:	Probability Sample

Study Population

Patients with Sd Cushing (CS): 40 women (25-60 years) with CS, with controlled hypercortisolism after treatment and without clinical / biochemical signs of relapse for more than 5 years.
Patients with acromegaly: 40 patients of both sexes (25-60 years) with GH / IGF-I controlled after treatment and without clinical / biochemical signs of relapse for more than 5 years.
Controls: n = 60; normal healthy control paired by age, sex and BMI will be included.

Criteria

Inclusion Criteria:

Patients with Cushing's syndrome or acromegaly who have been in remission for at least 5 years.

Exclusion Criteria:

Pregnancy, breastfeeding, chronic liver/kidney disease, chronic treatment with glucocorticoids.

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03673761

Contacts

Layout table for location contacts

Contact: Elena Valassi, MD, PhD	+34932919000 ext 1942	EValassi@santpau.cat

Locations

Layout table for location information

Spain
Hospital de la Santa Creu i Sant Pau	Recruiting
Barcelona, Please Select, Spain, 08025
Contact: Elena Valassi, MD, PhD +349329190000 ext 1942 EValassi@santpau.cat

Sponsors and Collaborators

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Martel-Duguech L, Alonso-Jiménez A, Bascuñana H, Díaz-Manera J, Llauger J, Nuñez-Peralta C, Biagetti B, Montesinos P, Webb SM, Valassi E. Thigh Muscle Fat Infiltration Is Associated With Impaired Physical Performance Despite Remission in Cushing's Syndrome. J Clin Endocrinol Metab. 2020 May 1;105(5). pii: dgz329. doi: 10.1210/clinem/dgz329.

Layout table for additonal information

Responsible Party:	Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
ClinicalTrials.gov Identifier:	NCT03673761
Other Study ID Numbers:	IIBSP-MIO-2017-41
First Posted:	September 17, 2018 Key Record Dates
Last Update Posted:	February 25, 2019
Last Verified:	February 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:	No

Layout table for additional information

Studies a U.S. FDA-regulated Drug Product:	No
Studies a U.S. FDA-regulated Device Product:	No

Keywords provided by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau:


muscle weakness myopathy

Additional relevant MeSH terms:

Layout table for MeSH terms

Acromegaly Muscle Weakness Cushing Syndrome Syndrome Disease Pathologic Processes Bone Diseases, Endocrine Bone Diseases Musculoskeletal Diseases Hyperpituitarism Pituitary Diseases	Hypothalamic Diseases Brain Diseases Central Nervous System Diseases Nervous System Diseases Endocrine System Diseases Muscular Diseases Neuromuscular Manifestations Neurologic Manifestations Adrenocortical Hyperfunction Adrenal Gland Diseases

To Top